RDInvesting Provides Investors with Free In-Depth Equity Reports on ACOR, AKBA, BSX and CYH

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Acorda Therapeutics Inc. (NASDAQ:ACOR - News) shares increased 1.93 percent to close at $35.87 a share Monday. The stock traded between $34.00 and $37.11 on volume of 1.52 million shares traded. Analysts at FBR Capital have recently upgraded the company’s rating to "outperform" from "market perform". Shares of Acorda Therapeutics have gained approximately 23.0 percent year-to-date.

Find out more about Acorda Therapeutics including full access to the free equity report at:
www.RDInvesting.com/ACOR

Akebia Therapeutics Inc. (NASDAQ:AKBA - News) shares soared 25.39 percent to close at $21.14 a share Monday. The stock traded between $17.07 and $23.32 on volume of 3.06 million shares traded. Analysts at Credit Suisse have recently initiated coverage on the company with an "outperform" rating and a price target of $25.00. Shares of Akebia Therapeutics have fallen approximately 20.0 percent since its IPO.

Find out more about Akebia Therapeutics including full access to the free equity report at:
www.RDInvesting.com/AKBA

Boston Scientific Corporation (NYSE:BSX - News) shares gained 4.89 percent to close at $13.31 a share Monday. The stock traded between $12.98 and $13.32 on volume of 16.74 million shares traded. Analysts at Bank of America-Merrill Lynch have recently upgraded the company’s rating to "buy" from "neutral". Shares of Boston Scientific have gained approximately 10.0 percent year-to-date.

Find out more about Boston Scientific including full access to the free equity report at:
www.RDInvesting.com/BSX

Community Health Systems (NYSE:CYH - News) shares 2.21 percent to close at $36.15 a share Monday. The stock traded between $35.85 and $37.00 on volume of 1.46 million shares traded. Analysts at Oppenheimer have recently upgraded the company’s rating to "outperform" from "perform". Shares of Community Health Systems have fallen approximately 8.0 percent year-to-date.

Find out more about Community Health Systems including full access to the free equity report at:
www.RDInvesting.com/CYH

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com